Uveitis, a rare but important complication of adjuvant zoledronic acid for early-stage breast cancer.
Journal
Anti-cancer drugs
ISSN: 1473-5741
Titre abrégé: Anticancer Drugs
Pays: England
ID NLM: 9100823
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
pubmed:
28
2
2023
medline:
14
3
2023
entrez:
27
2
2023
Statut:
ppublish
Résumé
Bisphosphonates such as zoledronic acid are an important part of adjuvant therapy to reduce the risk of recurrence in early-stage breast cancer. Uveitis remains one of the lesser-known side effects of zoledronic acid; prompt recognition is essential to ensure patients receive appropriate and timely care to help prevent permanent vision loss. We report a case of anterior uveitis in a postmenopausal woman who presented with visual symptoms after receiving the first dose of zoledronic acid. This case report serves to educate and increase awareness of the risk of uveitis in patients who are given zoledronic acid. This is the first and only reported case of zoledronic acid when used in the adjuvant setting for the treatment of breast cancer.
Identifiants
pubmed: 36846985
doi: 10.1097/CAD.0000000000001503
pii: 00001813-202304000-00014
doi:
Substances chimiques
Zoledronic Acid
6XC1PAD3KF
Bone Density Conservation Agents
0
Imidazoles
0
Diphosphonates
0
Adjuvants, Immunologic
0
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
592-594Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Eisen A, Somerfield MR, Accordino MK, Blanchette PS, Clemons MJ, Dhesy-Thind S, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update. J Clin Oncol 2022; 40:787–800.
Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015; 372:134–141.
Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83:1032–1045.
Gralow JR, Barlow WE, Paterson AH, M'iao JL, Lew DL, Stopeck AT, et al. Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. J Natl Cancer Inst 2020; 112:698–707.
O’Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2017; 10:Cd003474.
Samalia P, Sims J, Niederer R. Drug-induced ocular inflammation. N Z Med J 2020; 133:83–94.
Smith JR. Management of uveitis. Clin Exp Med 2004; 4:21–29.
Jin X, Shou Z, Shao Y, Bian P. Zoledronate-induced acute anterior uveitis: a three-case report and brief review of literature. Arch Osteoporos 2021; 16:104.
FDA package insert for zoledronic acid. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021223s028lbl.pdf .